Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1200P - BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib

Date

16 Sep 2021

Session

ePoster Display

Presenters

Renaud Descourt

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

R. Descourt1, M. Pérol2, G. Rousseau-Bussac3, D. Planchard4, B. Mennecier5, M. Wislez6, J. Cadranel7, A.B. Cortot8, F. Guisier9, L. Galland10, P. Do11, R. Schott12, E. Dansin13, J. Arrondeau14, J.B. Auliac15, C. Chouaid16

Author affiliations

  • 1 Finistère, CHRU Brest - Hopital Augustin Morvan, 29200 - Brest/FR
  • 2 Medical Oncology Dept., Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Pneumology, CHI Créteil, 94000 - Créteil/FR
  • 4 Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 5 Pathologie Respiratoire, Hopital Civil, 67000 - Strasbourg/FR
  • 6 Oncology Thoracic Unit Pulmonology Department, Hôpital Cochin, APHP, 75679 - Paris/FR
  • 7 Pneumology Department, APHP Paris - Hôpital Tenon, 75020 - Paris/FR
  • 8 Thoracic Oncology Department, Centre Hospitalier Régional Universitaire de Lille, 59000 - Lille/FR
  • 9 Department Of Pneumology, Hopital Charles-Nicolle - CHU de Rouen, 76031 - Rouen/FR
  • 10 Oncology Department, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 11 Medical Oncology, Centre Francois Baclesse, 14076 - Caen/FR
  • 12 Medical Oncology Department, ICANS - Institut de Cancérologie Strasbourg Europe, 67200 - Strasbourg/FR
  • 13 Thoracic Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 14 Medical Oncology, Hopital Cochin AP-HP, 75679 - Paris/FR
  • 15 Chest Department, CHI Créteil, 94000 - Creteil/FR
  • 16 Services De Pneumologie, CHI Créteil, Créteil/FR
More

Abstract 1200P

Background

Brigatinib is a next-generation ALK inhibitor (ALKi) approved in ALK+ advanced NSCLC (aNSCLC) pretreated with crizotinib and in first-line setting. The objective of BrigALK study was to assess efficacy of brigatinib during the French early access program (FEAP).

Methods

BrigALK study retrospectively included ALK+ aNSCLC pretreated with at least one ALKi during brigatinib FEAP. Primary endpoint was investigator-assessed progression-free survival (invPFS). BrigALK2 covered the entire EAP period and was an update of abstract 1392P presented at ESMO 2020 with a longer follow-up and a focus on lorlatinib efficacy after brigatinib.

Results

183 patients were included by 66 centers in France: median age: 60 ±12.7 years; never smokers: 78.3%; median number of previous lines: 3 ±1.3 and of ALKi: 2 ±0.5. 68.1% of patients had performance status 0-1 and 55.6 % more than 3 metastatic sites. With a median follow up of 40.5 (95%CI 38.4-42.4) months, median invPFS was 7.4 (95% CI: 5.9-9.6) months. Median duration of brigatinib treatment was 7.4 (95% CI 5.3-8.3) months. Median OS from brigatinib initiation was 20.3 months (95%CI: 15.6-27.6). For patients who received 1 (n=23), 2 (n=146) or 3 (n= 14) ALKi before brigatinib, median duration of treatment was 13.8 (95%CI 3.8-26.4), 7.4 (95%CI 5.6-9.9) and 4.9 (95%CI 1.7-9.3) months, respectively and median OS from brigatinib initiation was 24.3 (95%CI 9.7-NR), 20.3 (95%CI 16.2-28.7) and 18.1 (95%CI 3.3-34.5) months, respectively. 92 (50%) patients received at least 1 post-brigatinib treatment. 68 (73.9%) were treated with lorlatinib: 51 (75%) immediately after brigatinib, 12 (17.6%) after 1 subsequent treatment, 5 (7.4%) after at least 2 subsequent treatments. With a median follow-up of 29.9 (25.7-33.1) months, median duration of lorlatinib treatment was 5.3 (95% CI 3.6-7.6) months and median OS from lorlatinib initiation was 14.1 (95%CI 10.3-19.2) months.

Conclusions

The analysis of the EAP confirms the effectiveness of brigatinib in a cohort of heavily pretreated ALK-positive aNSCLC patients and the activity of subsequent ALKi after brigatinib.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

GFPC: Groupe Français de Pneumo-Cancérologie (French Lung Cancer Group).

Funding

Takeda.

Disclosure

R. Descourt: Financial Interests, Personal, Invited Speaker, advisory board: Takeda; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker, advisory board: Roche; Financial Interests, Personal, Invited Speaker: Novartis. M. Pérol: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal and Institutional, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Clovis Oncology; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Institutional, Funding: Chugai. G. Rousseau-Bussac: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Takeda. B. Mennecier: Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Institutional, Principal Investigator: Takeda. M. Wislez: Non-Financial Interests, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Roche; Non-Financial Interests, Institutional, Principal Investigator: BMS; Financial Interests, Personal, Speaker’s Bureau: BMS; Non-Financial Interests, Institutional, Principal Investigator: MSD; Financial Interests, Personal, Advisory Board: MSD; Non-Financial Interests, Institutional, Principal Investigator: Novartis; Financial Interests, Personal, Advisory Board: Novartis; Non-Financial Interests, Institutional, Principal Investigator: Lilly; Non-Financial Interests, Institutional, Principal Investigator: Merck KGaA; Non-Financial Interests, Institutional, Principal Investigator: Merus; Non-Financial Interests, Institutional, Principal Investigator: GSK; Non-Financial Interests, Institutional, Principal Investigator: Amgen; Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim. J. Cadranel: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Novartis. A.B. Cortot: Financial Interests, Personal, Advisory Board: AstraZeneca; Non-Financial Interests, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: BMS; Non-Financial Interests, Institutional, Principal Investigator: BMS; Financial Interests, Personal, Advisory Board: MSD; Non-Financial Interests, Institutional, Principal Investigator: MSD; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer; Non-Financial Interests, Institutional, Principal Investigator: Pfizer; Financial Interests, Personal, Advisory Board: Novartis; Non-Financial Interests, Institutional, Principal Investigator: Novartis; Financial Interests, Personal, Advisory Board: Takeda; Non-Financial Interests, Institutional, Principal Investigator: Takeda; Financial Interests, Personal, Advisory Board: Roche; Non-Financial Interests, Institutional, Principal Investigator: Roche. F. Guisier: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: AstraZeneca. R. Schott: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: BMS. J. Arrondeau: Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS. J.B. Auliac: Financial Interests, Personal, Invited Speaker, consulting: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker, consulting: F. Hoffman-Roche; Financial Interests, Personal, Invited Speaker, consulting: Lilly; Financial Interests, Personal, Invited Speaker, consulting: Pfizer. C. Chouaid: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Sanofi-Aventis; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings